Mesenchymal Stem Cells as Gene Delivery Vehicles by Porada, Christopher D. & Almeida-Porada, Graça
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Mesenchymal Stem Cells as Gene Delivery Vehicles
Christopher D. Porada and Graça Almeida-Porada
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53240
1. Introduction
Mesenchymal stem cells (MSCs) possess a battery of unique properties which make them
ideally suited not only for cellular therapies/regenerative medicine, but also as vehicles for
gene delivery in a wide array of clinical settings. These include: 1) widespread distribution
throughout the body; 2) ease of isolation and ability to be extensively expanded in culture
without loss of potential; 3) the ability to differentiate into a wide array of functional cell
types in vitro and in vivo; 4) they exert pronounced anti-inflammatory and immunomodula‐
tory effects upon transplantation; and 5) the ability to home to damaged tissues, solid tu‐
mors, and metastases following in vivo administration.
In this Chapter, we will summarize the latest research in the use of MSC in regenerative
medicine, focusing predominantly on their use as vehicles for transferring exogenous genes.
To highlight the immense potential these cells possess for gene therapy applications, we will
attempt to paint as broad a canvas as possible, starting with a discussion about the basic bi‐
ology of MSC, and their unique properties which combine to make MSC one of the most
promising stem cell populations for use in gene therapy studies and trials. We will reveal
the versatility of MSC as gene delivery vehicles by summarizing some of the most recent
studies showing the ease with which MSC can be modified with a wide range of both viral
and non-viral vector systems, and highlighting some of the advantages to delivering trans‐
genes within a cellular vehicle, as opposed to administering vectors directly into the body.
We will then discuss the engineering of MSC to enhance their natural abilities to mediate
repair within various tissues; one of the most popular uses of MSC to-date in the gene thera‐
py arena. We will discuss our recent work, and that of others, using MSC to deliver coagula‐
tion factors to treat the hemophilias, with hemophilia A serving as a paradigm for how MSC
could be used to deliver a therapeutic transgene, and thereby correct essentially any inherit‐
ed disease. The Chapter will conclude with a discussion of MSC’s ability to selectively mi‐
grate to forming solid tumors following intravenous administration, and to actively seek out
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metastases at sites far removed from the primary site of the tumor. We will summarize ex‐
citing recent work showing that it is possible to exploit this property to achieve sustained,
high-level expression of pro-apoptotic gene products within the tumor, obtaining greatly
improved anti-tumor effects, while essentially eliminating the systemic toxicities that plague
current radiation/chemotherapy-based treatments.
2. Isolation and characterization of MSC
More than 30 years ago, Friedenstein pioneered the concept that the marrow microenviron‐
ment resided within the so-called stromal cells of the marrow, by demonstrating that fibro‐
blastoid cells obtained from the bone marrow were capable of transferring the
hematopoietic microenvironment to ectopic sites [1, 2]. Years later, scientists began to ex‐
plore the full potential of these microenvironmental cells, and results of these studies led to
the realization that this population harbored cells with properties of true stem cells. These
cells were officially termed mesenchymal stem cells (MSC) [3]. MSC are now recognized to
be a key part of the microenvironment/niche that supports the hematopoietic stem cell and
drives the process of hematopoiesis, yet despite serving this vital function, MSC only com‐
prise ~0.001-0.01% of cells within the marrow [4], making methods for isolating/enriching
and for expanding these cells essential to their study and their ultimate clinical use. The
most straightforward method for obtaining MSC is to exploit their propensity to adhere to
plastic and their ability to be passaged with trypsin (contaminating hematopoietic cells do
not passage with trypsin) to rapidly obtain a relatively morphologically homogeneous pop‐
ulation of fibroblastic cells from a bulk mononuclear cell preparation [5-7]. Unfortunately,
true MSC (defined by function) account for only a small percentage of the highly heteroge‐
neous resultant population, making results obtained with cells prepared in this fashion diffi‐
cult to interpret, and inconsistent from experiment-to-experiment and from group-to-group.
The identification of antigens that are unique to MSC would eliminate this problem. Human
MSC do not express markers which have been associated with other stem cell populations
(like hematopoietic stem cells) such as CD34, CD133, or c-kit, nor hematopoietic markers
such as CD45, CD14, and CD19. Moreover, no marker has been identified to date that specif‐
ically identifies MSC. Nevertheless, several surface antigens have proven useful for obtain‐
ing highly enriched MSC populations. The first of these markers to be identified was Stro-1,
an antibody that reacts with non-hematopoietic bone marrow stromal precursor cells [8]. Al‐
though the antigen recognized by this antibody has not yet been identified, we and others
have found that by tri-labeling bone marrow cells with Stro-1, anti-CD45, and anti-GlyA,
and selecting the Stro-1+CD45-GlyA- cells, it is possible to consistently obtain a homogene‐
ous population that is highly enriched for MSC [9-15]. In addition to Stro-1, antibodies such
as SB-10, SH2, SH3, and SH4 have been developed over the years and numerous surface an‐
tigens such CD13, CD29, CD44, CD63, CD73, CD90, CD105, and CD166 have been used to
attempt to identify and isolate MSC [16-18]. Unfortunately, all of these antigens appear to be
expressed on a wide range of cell types within the body in addition to MSC. This lack of a
unique marker suggests that to obtain a pure population of MSC that are functionally homo‐
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geneous, investigators will likely either have to await the development of novel antibodies
that recognize as yet unidentified antigens that are unique to primitive MSC, or employ
strategies in which multiple antibodies are combined to allow for positive selection of MSC
and depletion of cells of other lineages that share expression of the antigens recognized by
the MSC antibody in question, as we have done with Stro-1, CD45, and GlyA.
3. Sources of MSC
Although much of the work to date has focused on MSC isolated from adult bone marrow,
we and others have isolated cells that appear phenotypically and functionally to be MSC,
from numerous tissues including brain, liver, lung, fetal blood, umbilical cord blood, kid‐
ney, and even liposuction material [19-26]. The broad distribution of MSC throughout the
body leads one to postulate that MSC may play a critical role in organ homeostasis by pro‐
viding supportive factors and/or mediating maintenance/repair within their respective tis‐
sue. Importantly, although MSC from each of these tissues appear similar with respect to
phenotype and overall differentiative potential, studies at the RNA and protein level have
now revealed that subtle differences exist between MSC from these various tissues, with
MSC from each tissue possessing a molecular fingerprint indicative of their tissue of origin
[21, 22, 27-31]. Using a non-injury fetal sheep transplantation model, we showed that these
differences result in a bias for human MSC to home to and give rise to cells of their tissue of
origin in vivo [32, 33]. This suggests that, to use MSC as therapeutics or as gene delivery ve‐
hicles, the ideal source of MSC may differ depending on the specific disease to be treated
and the desired target organ.
Despite the apparent presence of MSC within many of the major organs of the body, the rel‐
atively non-invasive fashion with which adipose tissue or bone marrow can be obtained,
and the fact that both these tissues could readily be obtained autologously, combine to sug‐
gest that these two tissues will likely be the predominant source of MSC employed in clini‐
cal applications in the foreseeable future. However, additional experiments will need to be
performed to rigorously assess the inherent safety of adipose tissue-derived MSC before
these cells will see widespread clinical use, since several recent studies have suggested that
they may be inherently less genetically stable than MSC isolated from bone marrow [34], ex‐
hibiting aneuploidy [35, 36] and undergoing transformation [37, 38] upon prolonged propa‐
gation in vitro. However, another recent study provided evidence that, even if genomic
instability is intentionally induced with genotoxic agents, adipose tissue-derived MSC re‐
spond to this insult by undergoing terminal adipogenic differentiation rather than transfor‐
mation [39]. The dramatically conflicting nature of the results from these different studies
could, perhaps, be due to differing methods employed for isolating and culturing MSC, dif‐
fering levels of contaminating non-MSC cells in the cultures, as well as the duration of the
culture (i.e., the number of times the cells have been passaged). Bearing this possible insta‐
bility in mind, the recommendation has been put forward to only make clinical use of cells
that have been passaged fewer than 25 times in culture, regardless of the source of MSC [40].
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4. MSC as vehicles for delivering therapeutic genes
While MSC possess tremendous therapeutic potential by virtue of their ability to lodge/
engraft within multiple tissues in the body and both give rise to tissue-specific cells and re‐
lease trophic factors that trigger the tissue’s own endogenous repair pathways [41-59], gene
therapists have realized that these properties are just the beginning of the therapeutic appli‐
cations for MSC [24, 60, 61]. By using gene therapy to engineer MSC to either augment their
own natural production of specific desired proteins or to enable them to express proteins
outside of their native repertoire, it is possible to greatly broaden the spectrum of diseases
for which MSC could provide therapeutic benefit. Unlike hematopoietic stem cells which are
notoriously difficult to modify with most viral vectors while preserving their in vivo poten‐
tial, MSC can be readily transduced with all of the major clinically prevalent viral vector sys‐
tems including those based upon adenovirus [62-64], the murine retroviruses [64-68],
lentiviruses [69-74], and AAV [75, 76], and efficiently produce a wide range of cytoplasmic,
membrane-bound, and secreted protein products. This ease of transduction coupled with
the ability to subsequently select and expand only the gene-modified cells in vitro to gener‐
ate adequate numbers for transplantation combine to make MSC one of the most promising
stem cell populations for use in gene therapy studies and trials.
To date, the majority of studies using gene-modified MSC have been undertaken with the
purpose of enhancing the natural abilities of MSC to mediate repair within various tissues.
Using the heart as an example, once investigators discovered the identity of some of the key
trophic factors responsible for MSC’s beneficial effect on the injured myocardium, they un‐
dertook studies using MSC engineered to overexpress a number of these factors [69, 77-86].
As anticipated, the “gene-enhanced” MSC were substantially more effective than their un‐
modified counterparts, producing greatly enhanced therapeutic effects. Similar studies have
also been performed to repair the damaged/diseased CNS using MSC engineered to pro‐
duce neurotrophic factors [87-94], to repair the injured liver using MSC expressing proteins
involved in hepatocyte differentiation and/or proliferation [95, 96], to repair ischemia/reper‐
fusion injury [97-102], and to repair the kidney [103-105]. In each case thus far, MSC engi‐
neered to express higher levels of proteins known to be beneficial for the tissue in question
and/or to promote survival have produced markedly better results than unmodified MSC.
Despite the many advantages of using MSC as gene delivery vehicles, however, relatively
few studies have thus far explored this potential for the treatment of genetic diseases. One
disease for which we and others are actively investigating MSC for delivery of a therapeutic
gene is hemophilia A [106-112].
5. Hemophilia A as a paradigm for the use of gene-modified msc to
correct genetic diseases
Hemophilia A represents the most common inheritable deficiency of the coagulation pro‐
teins [113]. The severity of hemophilia A is traditionally based on plasma levels of FVIII,
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with persons exhibiting less than 1% normal factor (<0.01 IU/mL) being considered to have
severe hemophilia, persons with 1-5% normal factor moderately severe, and persons with
5%-40% of the normal FVIII levels mild [114-116]. Up to 70% of hemophilia A patients
present with the severe form of the disease, and suffer from frequent hemorrhaging, leading
to chronic debilitating arthropathy, hematomas of subcutaneous connective tissue/muscle,
and internal bleeding. Over time, the collective complications of recurrent hemorrhaging re‐
sult in chronic pain, absences from school and work, and permanent disability [114]. Cur‐
rent state-of-the-art treatment consists of frequent prophylactic infusions of plasma-derived
or recombinant FVIII protein to maintain hemostasis, and has greatly increased life expect‐
ancy and quality of life for many hemophilia A patients.
This treatment approach is, however, far from ideal, due to the need for lifelong intravenous
infusions and the high treatment cost. Moreover, this treatment is unavailable to a large per‐
centage of the world’s hemophiliacs, placing these patients at great risk of severe, perma‐
nent disabilities and life-threatening bleeds. Furthermore, even among the patients who are
fortunate enough to have access to, and the financial means to afford, prophylactic FVIII in‐
fusions, approximately 30% will form FVIII inhibitors [117]. The formation of these inhibi‐
tors greatly reduces the efficacy of subsequent FVIII infusions, and can ultimately lead to
treatment failure, placing the patient at risk of life-threatening hemorrhage. There is thus a
significant need to develop novel, longer-lasting hemophilia A therapies.
In the past three decades, the remarkable progress in the understanding of the molecular ba‐
sis of the disease, the identification and characterization of FVIII gene, structure, and biolo‐
gy has heightened the interest and feasibility of treating hemophilia A with gene therapy. In
contrast to current protein-based therapeutics, lifelong improvement or permanent cure of
hemophilia A is theoretically possible after only a single gene therapy treatment; indeed,
several aspects of hemophilia A make it ideally suited for correction by gene therapy
[118-126]. First, in contrast to many other genetic diseases, the missing protein (coagulation
FVIII) does not need to be expressed in either a cell- or tissue-specific fashion to mediate cor‐
rection. Although the liver is thought to be the primary natural site of synthesis of FVIII, ex‐
pression of this factor in other tissues exerts no deleterious effects. As long as the protein is
expressed in cells which have ready access to the circulation, it can be secreted into the
bloodstream and exert its appropriate clotting activity. Second, even modest levels (3-5%) of
FVIII-expressing cells would be expected to convert severe hemophilia A to a moderate/
mild phenotype, reducing or eliminating episodes of spontaneous bleeding and greatly im‐
proving quality of life. Thus, even with the low levels of transduction that are routinely ob‐
tained with many of the current viral-based gene delivery systems, a marked clinical
improvement would be anticipated in patients with hemophilia A. Conversely, even supra‐
physiologic levels of FVIII as high as 150% of normal are predicted to be well tolerated,
making the therapeutic window extremely wide [116]. Based on this knowledge, the Ameri‐
can Society of Gene and Cell Therapy (www.ASGCT.org) recently provided NIH director,
Dr. Francis Collins, with a roadmap of disease indications that it feels will be viable gene
therapy products within the next 5-7 years. The hemophilias were identified as belonging to
the most promising, “Target 10”, group of diseases.
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6. Mesenchymal Stem Cells (MSC) as hemophilia A therapeutics
As discussed in the preceding section, the liver is thought to be the primary site of FVIII syn‐
thesis within the body. We and others have devoted a great deal of energy to demonstrating
the ability of MSC from various sources to serve as therapeutics for liver disease [11, 13, 14,
33, 96, 127-152]. It is now clear that, not only do MSC have the ability to generate, in vitro
and in vivo, cells which are indistinguishable from native hepatocytes, but transplantation
of MSC in a range of model systems can result in fairly robust formation of hepatocytes
which repair a variety of inborn genetic defects, toxin-induced injuries, and even fibrosis.
The fetal sheep model provides a unique system in which to explore the full differentiative
potential of various stem cell populations, since the continuous need for new cells within all
of the organs during fetal development provides a permissive milieu in which gene-modi‐
fied donor cells can engraft, proliferate, and differentiate. Furthermore, by performing the
transplant at a stage in gestation when the fetus is considered to be largely immuno-naïve, it
is possible to engraft human cells at significant levels, which persist for the lifespan of the
animal due to induction of donor-specific tolerance [130-132]. Indeed, in ongoing studies,
we have found that, after transplantation into fetal sheep, human MSC engraft at levels of
up to 12% within the recipient liver [11, 131, 132, 153-158], and contribute to both the paren‐
chyma and the perivascular zones of the engrafted organs, placing them ideally for deliver‐
ing FVIII into the circulation. Since FVIII levels of 3-5% of normal would convert a patient
with severe hemophilia A to a moderate or mild phenotype, these levels of engraftment
should be highly therapeutic. These collective results thus suggest that MSC may represent
an ideal cell type for treating hemophilia A.
However, although MSC engrafted (following transplantation in utero) at significant levels
within organs that are natural sites of FVIII synthesis, only a small percent expressed endog‐
enous FVIII, suggesting that simply transplanting “healthy” MSC will not likely provide an
effective means of treating/curing hemophilia A. By using gene therapy to engineer MSC to
express FVIII, however, it is highly probable that the levels of engrafted MSC we have thus
far achieved in utero would provide marked therapeutic benefit in hemophilia A. By trans‐
ducing the MSC in vitro, rather than performing gene therapy by injecting the vector direct‐
ly, as is the current practice in clinical gene therapy trials, there is no risk of off-target
transduction, and the vector being employed simply needs a strong constitutively active
promoter to ensure that all cells derived from the transplanted MSC continue to express
FVIII and mediate a therapeutic effect. Importantly, the only documented cases of retroviral-
induced insertional mutagenesis have been observed following genetic modification of hem‐
atopoietic stem cells [159-161]; there is no evidence that MSC transform or progress to clonal
dominance following transduction, suggesting they represent safe cellular vehicles for deliv‐
ering FVIII (or other transgenes).
Importantly, critical proof-of-principle studies have already shown that MSC can be trans‐
duced with FVIII-expressing viral vectors and secrete high levels of FVIII protein in vitro
and following transplantation in vivo [106-109]. FVIII purified from the conditioned medi‐
um of the transduced MSC was proven to have a specific activity, relative electrophoretic
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mobility, and proteolytic activation pattern that was virtually identical to that of FVIII pro‐
duced by other commercial cell lines [109]. Given the widespread distribution and engraft‐
ment of MSC following their systemic infusion, the ability of MSC to give rise, in vivo, to
cells of numerous tissue types, and their ability to efficiently process and secrete high
amounts of biologically active FVIII, they are, not surprisingly, being viewed as ideal vehi‐
cles for delivering a FVIII transgene throughout the body and thus providing long-term/
permanent correction of hemophilia A [106-109, 162].
In addition to their widespread engraftment and their ability to serve as delivery vehicles
for the FVIII gene, the rather unique immunological properties of MSC may further increase
their utility for treating hemophilia A. MSC do not normally express MHC class II or the co-
stimulatory molecules CD80 and CD82, unless they are stimulated with IFN-γ, and are thus
viewed as being relatively hypo-immunogenic. As such, they do not provoke the prolifera‐
tion of allogeneic lymphocytes or serve as very effective targets for lysis by cytotoxic T cells
or NK cells. In fact, a large body of evidence is now accumulating that MSC can be readily
transplanted across allogeneic barriers without eliciting an immune response [163, 164].
Thus, if one wished to use MSC to treat hemophilia A, off-the-shelf MSC from an unrelated
donor could theoretically be used, greatly increasing the feasibility of obtaining and using
these stem cells for therapy.
Perhaps even more important from the standpoint of their potential use as hemophilia A
therapeutics, more recent studies have provided evidence that MSC also appear to have the
ability to exert both immunosuppressive and anti-inflammatory properties both in vitro and
in vivo. These properties appear to result from MSC’s ability to intervene, at multiple levels,
with the generation and propagation of an immune response. To name just a few examples,
MSC have been demonstrated to interfere with the generation and maturation of cytotoxic
and helper T cells [165-174], dendritic cells [175-178], and B cells [179]. In addition to actively
shutting down the generation of immune effector cells, MSC also have the ability to induce
the formation of potent Tregs, although the mechanism by which this comes about is still the
subject of active research [40, 180-182]. MSC are also known to express a battery of factors
[40, 168-170, 180, 183-187] that reduce local inflammation, blunt immune response, and
counteract the chemotactic signals responsible for recruiting immune cells to sites of injury/
inflammation. One could thus envision these immune-dampening properties enabling the
delivery of FVIII without eliciting an immune response and subsequent inhibitor formation,
thus overcoming one of the major hurdles that plague current treatment/management of he‐
mophilia A. As will be discussed in the next section, however, our postnatal studies in the
hemophilic sheep suggest that further work will be required to discover how to obtain these
potential immune benefits in the context of the ongoing injury/inflammation present in ani‐
mals/patients with clinically advanced hemophilia A.
In addition to the aforementioned properties, preclinical animal studies examining the po‐
tential of MSC isolated from adult tissues have also highlighted another interesting and clin‐
ically valuable characteristic of MSC; their ability to selectively navigate to sites of injury
and/or inflammation within the body. Once reaching these specific sites, the MSC then me‐
diate repair both by engrafting and generating tissue-specific cells within the injured tissue
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[188-190], and by releasing trophic factors that blunt the inflammatory response and often
promote healing by activating the tissue’s own endogenous repair mechanisms. While the
mechanisms responsible for this trafficking to sites of injury are still being elucidated
[191-193], this observation raises the exciting possibility that, following systemic infusion,
FVIII-expressing MSC could efficiently migrate to sites of active bleeding/injury, thereby re‐
leasing FVIII locally and focusing the therapy where it is most needed. As will be discussed
in the following section, over the past 2-3 years, we have begun exploring whether it is pos‐
sible to exploit these many advantages of MSC as a cellular vehicle for delivering a FVIII
gene by testing the ability of FVIII-expressing MSC to correct hemophilia A in a new large
animal model; sheep.
7. Establishment of a new preclinical model of hemophilia A and success
with MSC-based treatment
A number of animal models have been developed to evaluate new methods of not only
treatment of coagulation disorders, but also the prevention and treatment of inhibitor for‐
mation. Transient hemophilic rabbit models induced by infusion of plasma containing in‐
hibitors have been used to evaluate the effect of different bypass products to factor VIII
[194], but these models, while valuable for inhibitor studies, do not accurately recapitulate
the human disease, precluding their use for gene therapy studies. Fortunately, dog models
of hemophilia A with congenital deficiency [195, 196] and mouse models obtained by gene
targeting and knockout technology [197] are available to study FVIII function and gene ther‐
apy approaches for treating hemophilia A. Therapeutic benefit has been obtained in numer‐
ous studies using a variety of vector systems in the murine model [121, 122, 198-204], and
phenotypic correction of hemophilia A in the dog has been achieved, but has proven to be
far more difficult than in mice [205, 206]. Despite promising results in both canine and mur‐
ine models, however, no clinical gene therapy trial has shown phenotypic/clinical improve‐
ment of hemophilia A in human patients. This is in marked contrast to the recent clinical
successes with gene therapy for hemophilia B [207]. The reasons for the disparity in the effi‐
cacy of gene therapy for treating hemophilia A versus B is not presently clear. Nonetheless,
based on the disappointing results to-date, there are currently no active hemophilia A clini‐
cal gene therapy trials, even though hemophilia A accounts for roughly 80% of all cases of
hemophilia.
The difficulties seen thus far translating success in animal models into therapeutic benefit in
human patients underscores the importance of preclinical animal models that both precisely
mimic the disease process of hemophilia A, and closely parallel normal human immunology
and physiology. To this end, between 1979 and 1982, a number of male offspring of a single
white alpine ewe at the Swiss Federal Institute of Technology all died several hours post-
partum due to severe bleeding from the umbilical cord [208-210]. Daughters and grand‐
daughters of this ewe also gave birth to lambs exhibiting the same pathology. Investigation
of the affected animals showed extensive subcutaneous and intramuscular hematomas.
Spontaneous hemarthroses were also frequent, leading to reduced locomotion and symp‐
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toms of pain in standing up, restricting nursing activity. Stronger injuries that arose when
animals were not placed in carefully controlled isolation resulted in heavy bleeding and in‐
tensive pain. Laboratory tests showed increased PTT, and FVIII levels (as assessed by aPTT)
of about 1% of control animals. Replacement therapy with human FVIII (hFVIII) concentrate
or fresh sheep plasma resulted in remission of disease and rapid clinical improvement.
Unfortunately, due to the expense and effort of maintaining these sheep, the Swiss investi‐
gators allowed the line to die out, saving only a few straws of semen prior to allowing this
valuable resource to pass into extinction. We recently used a variety of reproductive tech‐
nologies to successfully re-establish this line of hemophilia A sheep, and fully characterized
both the clinical parameters and the precise molecular basis for their disease [211-216]. In
similarity to mutations seen in many human patients [217], these animals possess a prema‐
ture stop codon with a frameshift mutation. This is the only animal model of hemophilia A
with this clinically relevant mutation-type, providing a unique opportunity to study thera‐
pies in this context. All ten animals to-date have exhibited bleeding from the umbilical cord,
prolonged tail and “cuticle” bleeding time, and multiple episodes of severe spontaneous
bleeding including hemarthroses, muscle hematomas, and hematuria, all of which have re‐
sponded to human FVIII. Just like human patients with severe hemophilia A, a hallmark
symptom in these sheep is repeated spontaneous joint bleeds, which lead to chronic, debili‐
tating arthropathies and reduced mobility. Importantly, chromogenic assays performed in‐
dependently at the BloodCenter of Wisconsin and Emory University revealed undetectable
FVIII activity in the circulation of these sheep, explaining their severe, life-threatening phe‐
notype.
In addition to the value of another large animal model of hemophilia A and the uniqueness
of the mutation, sheep possess many characteristics that make them an ideal preclinical
model for gene therapy. The first of these is the size. Sheep are fairly close in size to humans,
weighing roughly 8lbs at birth and 150-200lbs as adults, likely obviating the need for scale-
up of cell/vector dose to move from experiments in sheep to trials in humans. This is in
marked contrast to mice which are ~2800 times smaller than a typical human patient [218].
Secondly, sheep share many important physiological and developmental characteristics
with humans; for example, the pattern of fetal to adult hemoglobin switching, and the natu‐
rally occurring changes in the primary sites of hematopoiesis from yolk sac to fetal liver and
finally to the bone marrow near the end of gestation. Thirdly, sheep are outbred, and thus
represent a wide spectrum of genetic determinants of the immune response, as do humans.
As the immune response to both the vector and the vector–encoded FVIII are likely to play a
key role in FVIII inhibitor formation (or lack thereof), this represents an advantage not
found in most other models, with the possible exception of the dog, which could conceiva‐
bly be outbred as well to achieve a broader genetic spectrum. In addition, the development
of the sheep immune system has been investigated in detail [219-225], making sheep well
suited for studying the immunological aspects of gene-based therapies for hemophilia A.
Importantly, the large size of the sheep, their long life span (9-12 years), and their relative
ease of maintenance and breeding make it possible to conduct long-term studies in relative‐
ly large numbers of animals to fully evaluate the efficacy and safety issues related to gene
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therapy. For these reasons, we feel that the sheep are a particularly relevant model in which
to examine gene and cell-based therapies for hemophilia A. An additional unique advantage
to using sheep to study hemophilia A treatment is that in sheep, like human, a large percent‐
age of the vWF is found within platelets rather than free in plasma. This is in contrast to dog
(in which vWF circulates free in plasma [226, 227]), and makes the sheep an ideal large ani‐
mal model in which to explore the use of platelet-targeted gene therapy for hemophilia A
[126, 228-230].
To experimentally test the ability of MSC to serve as FVIII delivery vehicles and thus treat
hemophilia A, we recently tested a novel, non-ablative transplant-based gene therapy in 2
pediatric hemophilia A lambs [110-112]. During the first 3-5 months of life, both these ani‐
mals had received frequent, on-demand infusions of human FVIII for multiple hematomas
and chronic, progressive, debilitating hemarthroses of the leg joints which had resulted in
severe defects in posture and gait, rendering them nearly immobile. In an ideal situation,
one would use autologous cells to deliver a FVIII transgene, and thus avoid any complica‐
tions due to MHC-mismatching. Unfortunately, the severe life-threatening phenotype of the
hemophilia A sheep prevented us from collecting bone marrow aspirates to isolate autolo‐
gous cells. We therefore elected to utilize cells from the ram that had sired the two hemo‐
philiac lambs, hoping that, by using paternal (haploidentical) MSC, immunologic
incompatibility between the donor and recipient should be minimized sufficiently to allow
engraftment, especially given the large body of evidence now accumulating that MSC can be
transplanted across allogeneic barriers without eliciting an immune response [163, 164].
Based on our prior work in the fetal sheep model, we knew that the intraperitoneal (IP)
transplantation of MSC results in widespread engraftment throughout all of the major or‐
gans [11, 131, 157, 231-233] and durable expression of vector-encoded genes [232-234]. We
further reasoned that using the IP route would also have the advantage of enabling the cells
to enter the circulation in an almost time-release fashion, after being engulfed by the omen‐
tum and absorbed through the peritoneal lymphatics. Importantly, we also felt that the use
of the IP route would enable us to avoid the lung-trapping which hinders the efficient traf‐
ficking of MSC to desired target organs following IV administration, and also poses clinical
risks due to emboli formation [235, 236].
Following isolation, MSC were simultaneously transduced with 2 HIV-based lentivectors,
the first of which encoded an expression/secretion optimized porcine FVIII (pFVIII) trans‐
gene [112]. We selected a pFVIII transgene for two reasons. First, we had not yet cloned the
ovine FVIII cDNA and constructed a B domain-deleted cassette that would fit in a lentivec‐
tor. Secondly, the pFVIII transgene had previously been shown, in human cells, to be ex‐
pressed/secreted at 10-100 times higher levels than human FVIII [120, 121, 237]. We thus felt
that these very high levels of expression/secretion might enable us to achieve a therapeutic
benefit, even in the event we obtained very low levels of engraftment of the transduced pa‐
ternal MSC. The second lentivector encoded eGFP to facilitate tracking and identification of
donor cells in vivo. Combining the 2 vectors unexpectedly resulted in preferential transduc‐
tion with the eGFP vector, such that only about 15% of the MSC were transduced with the
pFVIII-encoding vector, as assessed by qPCR. Once the transduced MSC had been suffi‐
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ciently expanded, the first animal to be transplanted was treated with a dose of hFVIII calcu‐
lated to correct the levels to 200%, to ensure no procedure-related bleeding occurred. The
animal was then sedated, and 30x10^6 transduced MSC were transplanted into the perito‐
neal cavity under ultrasound guidance in the absence of any preconditioning.
Following transplantation, FVIII activity (assessed by chromogenic assay) was undetectable
in the circulation, but this animal’s clinical picture improved dramatically. All spontaneous
bleeding events ceased, and he enjoyed an event-free clinical course, devoid of spontaneous
bleeds, enabling us to cease hFVIII infusions. Existing hemarthroses resolved, the animal’s
joints recovered fully and resumed normal appearance, and he regained normal posture and
gait, resuming a normal activity level. To our knowledge, this represents the first report of
phenotypic correction of severe hemophilia A in a large animal model following transplan‐
tation of cells engineered to produce FVIII, and the first time that reversal of chronic debili‐
tating hemarthroses has been achieved.
Based on the remarkable clinical improvement we had achieved in this first animal, we
transplanted a second animal with 120x10^6 paternal MSC, >95% of which were transduced
and expressing pFVIII. We anticipated that by transplanting 4x’s the number of cells with
roughly 6x’s the transduction efficiency, we would achieve pronounced improvement and
therapeutic levels of FVIII in the circulation of this animal. In similarity to the first animal,
hemarthroses present in this second animal at the time of transplant resolved, and he re‐
sumed normal activity shortly after transplantation. This second animal also became factor-
independent following the transplant. These results thus confirm the ability of this MSC-
based approach to provide phenotypic correction in this large animal model of hemophilia
A. However, just as we had observed in the first animal, no FVIII was detectable in the cir‐
culation of this animal, making the mechanism by which this procedure mediated such pro‐
nounced clinical improvement uncertain.
Despite the pronounced clinical improvement we observed in the first animal, he mounted a
rapid and fairly robust immune response to FVIII, in similarity to prior studies performed
with hemophilia A mice [237]. Before transplant, this first animal had Bethesda titers against
hFVIII of only ~3, yet this lifesaving procedure resulted in a rise in Bethesda titer to ~800
against the vector-encoded pFVIII and nearly 700 to hFVIII. The formation of such high titer
inhibitors with cross-reactivity to the human protein was surprising, given the well estab‐
lished ability to successfully use porcine FVIII products in human patients to bypass exist‐
ing anti-hFVIII inhibitors [238-241]. Similarly, despite having no detectable inhibitors prior
to transplant, the second animal receiving the higher FVIII-expressing cell dose developed
titers of ~150 Bethesda units against the vector-encoded pFVIII following transplantation
which also exhibited cross-reactivity to the human protein.
Following euthanasia of these animals, we performed a detailed tissue analysis to begin de‐
ciphering the mechanism whereby this novel MSC-based gene delivery produced its pro‐
nounced therapeutic effect at a systemic level. PCR analysis demonstrated readily detectable
levels of MSC engraftment in nearly all tissues analyzed, including liver, lymph nodes, in‐
testine, lung, kidney, omentum, and thymus. These molecular analyses thereby proved that
it is possible to achieve widespread durable engraftment of MSC following transplantation
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in a postnatal setting in a large animal model without the need for preconditioning/ablation,
and in the absence of any selective advantage for the donor cells.
Confocal immunofluorescence analysis revealed large numbers of FVIII-expressing MSC
within the synovium of the joints which exhibited hemarthrosis at the time of transplant,
demonstrating (just as we had hoped/predicted) that the transplanted MSC possessed the
intrinsic ability to home to and persist within sites of ongoing injury/inflammation, releasing
FVIII locally within the joint, providing an explanation for the dramatic improvement we
observed in the animal’s joints. This finding is in agreement with prior studies [242], show‐
ing that local delivery of FIX-AAV to the joints of mice with injury-induced hemarthroses
led to resolution of the hemarthroses in the absence of any detectable FIX in the circulation.
While this finding provides an explanation for the reversal of the joint pathology present in
these animals at transplant, it cannot explain the observed systemic benefits such as the ces‐
sation of spontaneous bleeding events.
Confocal analysis also revealed engrafted cells within the small intestine, demonstrating
that MSC can still engraft within the intestine following postnatal transplantation, just as we
had observed in prior studies in fetal recipients [232]. Given the ease with which proteins
secreted from cells within the intestine can enter the circulation, future studies aimed at im‐
proving the levels of engraftment within the intestine have the potential to greatly improve
the systemic release of FVIII. In addition to the intestine and hemarthrotic joints, significant
levels of engraftment were also seen within the thymus of this animal. While the ability of
the transplanted MSC to traffic to the thymus could clearly have important implications for
the likelihood of long-term correction with this approach to hemophilia A treatment, addi‐
tional studies are required to determine with which cells within the thymus these MSC are
interacting to ascertain the immunologic ramifications of thymic engraftment.
The marked phenotypic improvement and improvement in quality of life we have observed
in our studies, to date, in the sheep model thus support the further development of thera‐
peutic strategies for hemophilia A and, perhaps, other coagulation disorders, employing
MSC as cellular vehicles to deliver the required transgene.
8. MSC as anti-cancer gene delivery vehicles
As alluded to earlier, a large number of preclinical animal studies examining the differentia‐
tive potential of MSC isolated from a variety of adult tissues have also highlighted another
interesting and clinically valuable characteristic of MSC; their ability to selectively navigate
to sites of injury and/or inflammation within the body [192, 193, 243-247]. Once reaching
these specific sites, the MSC then mediate repair both by engrafting and generating tissue-
specific cells within the injured tissue (but contributing very little if at all to other tissues
that are functionally normal [188-190]), and by releasing trophic factors that blunt the in‐
flammatory response and often promote healing by activating the tissue’s own endogenous
repair mechanisms. While the mechanisms responsible for this trafficking to sites of injury
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are currently not well understood, this observation has raised the exciting prospect of using
MSC to treat a wide array of diseases in which inflammation plays a key role such as stroke
[87, 88, 92, 248-255], rheumatoid arthritis [256], asthma [257-259] and allergic rhinitis [260],
and both acute and chronic lung injury [261].
Cancer represents another condition in which there is a selective need for new cells created
by the forming tumor, and a chronic state of insult/inflammation within the surrounding tu‐
mor microenvironment. Studies over the last several years have now revealed that MSC
have the ability to “sense” this need for cells and the perceived injury to the tissue surround‐
ing the tumor. As a result, both endogenous bone marrow- and adipose-resident MSC, as
well as intravenously infused MSC, all appear to have the ability to efficiently migrate to the
forming tumor, and contribute to the newly forming tumor “stroma” [191, 262-266]. Clearly,
this may not seem ideal, since the MSC could, in fact, provide support to the growing tu‐
mor, potentially worsening the prognosis. Indeed, unraveling the role played by MSC with‐
in the tumor microenvironment is currently an area of active research [191, 192, 262-265,
267-269]. Irrespective of their role in the tumor’s health/biology, however, the ability of MSC
to selectively traffic to and integrate into the tumor microenvironment can be viewed as a
double-edged sword, since this ability has now been recognized to present a very powerful
and unique means of selectively delivering anti-cancer gene products to tumor cells in vivo
[270-274]. Four of the gene products which have thus far received the most attention are IL-2
[275, 276], IL-12 [277-284], IFN-β [270, 271, 285, 286], and tumor necrosis factor-related apop‐
tosis-inducing ligand (TRAIL) [287-298]. Unfortunately, the utility of these and many other
biological agents that could be used for cancer therapy is often limited by both their short
half-life in vivo and their pronounced toxicity due to effects on normal, non-malignant cells
within the body. Using MSC to deliver these therapeutics promises to solve both of these
problems, since the MSC can selectively migrate to the tumor site and release their therapeu‐
tic payload locally. This would be predicted to greatly increase the agent’s concentration
within the tumor and significantly lower its systemic toxicity. In addition, by genetically
modifying the MSC with viral vectors, the engrafted MSC will steadily release the therapeu‐
tic agent, allowing a single administration to result in long-lasting effects. Other studies
have now provided evidence that MSC have the ability to not only selectively home to solid
tumors [270, 271, 287, 299], but also to actively seek out metastases at sites far removed from
the primary site of the tumor [271, 288, 290, 299, 300]. This ability has recently been proven
to be of great therapeutic value in the treatment of lung metastases arising from both breast
cancer and melanoma in a murine xenograft model [271, 299]. Given the difficulty and fre‐
quent lack of success using traditional approaches such as surgery, radiotherapy, and che‐
motherapeutic agents to treat tumors which are either highly invasive or prone to
metastasis, this property of MSC will likely prove to be of great clinical value in the near
future.
One form of cancer for which the use of MSC is receiving a great deal of attention is glio‐
blastoma multiforme (GBM). GBM represents the most common form of malignant glioma.
Despite decades of research and many advances in the treatment of this disease with con‐
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ventional surgery, radiotherapy, and chemotherapy, there is no cure, and the current prog‐
nosis is abysmal, with a median survival of only 6-18 months. The failure of current
therapies to cure this disease arises predominantly from the highly invasive nature of this
cancer and the inability of these agents to effectively target tumor cells which have dissemi‐
nated into the normal parenchyma of the brain, at sites distant from the main tumor mass.
Given the ability of MSC to home to tumors and their ability to track to metastases through‐
out the body, gene-modified MSC are receiving a great deal of attention as a possible thera‐
py for GBM. Studies have now shown that MSC migrate through the normal brain
parenchyma towards gliomas and appear to possess the uncanny ability to track microscop‐
ic tumor deposits and individual tumor cells which have infiltrated the normal brain paren‐
chyma [276, 282, 289, 290, 301-310]. While these migratory properties are certainly
interesting, even more exciting are the dramatic therapeutic benefits these same studies have
shown, with reduction in tumor size, and pronounced improvements in survival. It is im‐
portant to note that, in most of these studies, MSC were used as the sole therapy, and defi‐
nite benefits were observed. In the clinical setting, the current plan is to use gene-modified
MSC as an adjunct after surgical resection. In this scenario, the vast majority of the tumor
mass would be surgically removed, and the MSC would then be transplanted, in the hopes
that they would then remove the residual malignant cells at the site of the tumor, and then
hunt down and eliminate any invasive tumor cells that have migrated away from the site of
the primary tumor. In this context, one would imagine that the therapeutic benefit of the
MSC will likely be even more pronounced, since their anti-tumor effects could be focused
only on the small number of residual tumor cells that evaded removal during surgery. The
remarkable success seen in studies aimed at treating GBM, one of the most devastating
forms of cancer, thus serve to highlight the tremendous potential MSC harbor as gene deliv‐
ery vehicles for the treatment of many forms of cancer for which current therapeutic strat‐
egies are ineffective.
9. Conclusions
Numerous investigators  around the globe have now provided compelling evidence that
MSC from a variety of tissues possess a far broader differentiative capacity than anyone
would have foreseen at  the  time Friedenstein  originally  described his  bone marrow-de‐
rived stromal cells. Extrapolating the work thus far on using MSC to deliver FVIII to treat
hemophilia A, and the rapidly growing number of studies showing the tremendous po‐
tential of MSC as anti-cancer gene delivery vehicles, and combining this with the relative
ease with which MSC can be isolated, propagated in culture, and modified with a variety
of viral-based vectors,  and their  intrinsic  ability to seek out sites  of  injury/inflammation
within the body, one can readily see why MSC are widely viewed as being ideally suited
not only as cellular therapeutics, but as vehicles to deliver gene therapy vectors to numer‐
ous tissues in the body, thus promising to provide a permanent cure for a diverse range
of diseases.
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